PVR and small cell lung carcinoma: We found expression of PVR, indoleamine 2,3‐dioxygenase, MHCII, and TIM3 to be increased in the NE‐low subtype, highlighting these molecules as potential biomarkers and targets for SCLC immunotherapies.